JP2025502749A5 - - Google Patents
Info
- Publication number
- JP2025502749A5 JP2025502749A5 JP2024538421A JP2024538421A JP2025502749A5 JP 2025502749 A5 JP2025502749 A5 JP 2025502749A5 JP 2024538421 A JP2024538421 A JP 2024538421A JP 2024538421 A JP2024538421 A JP 2024538421A JP 2025502749 A5 JP2025502749 A5 JP 2025502749A5
- Authority
- JP
- Japan
- Prior art keywords
- cysteine
- glutamine
- lysine
- liver
- alanine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR10-2021-0185350 | 2021-12-22 | ||
| KR1020210185350A KR20230095665A (ko) | 2021-12-22 | 2021-12-22 | 간 표적 약물 및 이의 용도 |
| PCT/KR2022/021130 WO2023121371A1 (ko) | 2021-12-22 | 2022-12-22 | 간 표적 약물 및 이의 용도 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2025502749A JP2025502749A (ja) | 2025-01-28 |
| JP2025502749A5 true JP2025502749A5 (enExample) | 2026-01-06 |
Family
ID=86903128
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024538421A Pending JP2025502749A (ja) | 2021-12-22 | 2022-12-22 | 肝臓標的薬物及びその用途 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20250114463A1 (enExample) |
| EP (1) | EP4454658A4 (enExample) |
| JP (1) | JP2025502749A (enExample) |
| KR (1) | KR20230095665A (enExample) |
| CN (1) | CN118891057A (enExample) |
| WO (1) | WO2023121371A1 (enExample) |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6096871A (en) | 1995-04-14 | 2000-08-01 | Genentech, Inc. | Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life |
| ATE279947T1 (de) | 1996-03-18 | 2004-11-15 | Univ Texas | Immunglobulinähnliche domäne mit erhöhten halbwertszeiten |
| AU2007240313B2 (en) * | 2006-04-20 | 2012-02-02 | Amgen Inc. | GLP-1 compounds |
| KR101512702B1 (ko) | 2012-05-23 | 2015-04-16 | 포항공과대학교 산학협력단 | 금속 나노 입자 기반 간 표적 지향 약물 전달체 및 이의 제조방법 |
| US9340600B2 (en) * | 2012-06-21 | 2016-05-17 | Indiana University Research And Technology Corporation | Glucagon analogs exhibiting GIP receptor activity |
| JP6712323B2 (ja) * | 2015-12-31 | 2020-06-17 | ハンミ ファーマシューティカル カンパニー リミテッド | グルカゴン、ｇｌｐ−１及びｇｉｐ受容体のすべてに活性を有する三重活性体 |
| SG11202105435PA (en) | 2019-06-28 | 2021-06-29 | Hanmi Pharmaceutical Co Ltd | Therapeutic use of trigonal glucagon/glp-1/gip receptor agonist or conjugate thereof for liver disease |
| JP2023521491A (ja) * | 2020-04-20 | 2023-05-24 | ハンミ ファーマシューティカル カンパニー リミテッド | グルカゴン、ｇｌｐ－１及びｇｉｐ受容体の全てに対して活性を有する三重活性体又はその結合体を含む高脂血症の予防又は治療用薬学的組成物及び予防又は治療方法 |
| EP4183419A4 (en) * | 2020-07-17 | 2025-04-02 | Hanmi Pharm. Co., Ltd. | THERAPEUTIC USE OF A COMBINATION WITH A LONG-ACTING TRIPLE AGONIST CONJUGATE OR TRIPLE AGONIST |
-
2021
- 2021-12-22 KR KR1020210185350A patent/KR20230095665A/ko active Pending
-
2022
- 2022-12-22 EP EP22912004.3A patent/EP4454658A4/en active Pending
- 2022-12-22 WO PCT/KR2022/021130 patent/WO2023121371A1/ko not_active Ceased
- 2022-12-22 CN CN202280092139.6A patent/CN118891057A/zh active Pending
- 2022-12-22 JP JP2024538421A patent/JP2025502749A/ja active Pending
- 2022-12-22 US US18/723,182 patent/US20250114463A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN111278853B (zh) | 基于胃泌酸调节素类似物glp-1r/gcgr双靶点激动剂多肽治疗胆汁性肝硬化 | |
| JP2019504055A5 (enExample) | ||
| CA2786090A1 (en) | Interferon analogs | |
| WO2010042548A2 (en) | Methods of treating inflammation | |
| CN112791178B (zh) | Glp-1r/gcgr双激动剂多肽衍生物预防或治疗肾纤维化 | |
| JP2023521491A5 (enExample) | ||
| JP2024028915A (ja) | 好中球の活性化に関連する疾患を処置するための抗凝固性タンパク質およびそれらの使用 | |
| US7476655B2 (en) | Materials and methods for regulating blood flow | |
| CN111372945B (zh) | 基于胃泌酸调节素类似物glp-1r/gcgr双靶点激动剂多肽治疗特发性肺间质纤维化 | |
| EP4228691A2 (en) | Lung treatment compositions | |
| US20140235541A1 (en) | Compositions and methods for treatment of aortic fibrosis | |
| CN114246937B (zh) | 白细胞介素37与干扰素联用在治疗病毒感染中的应用 | |
| JP2014519514A5 (enExample) | ||
| CN114585640B (zh) | Glp-1r/gcgr双靶点激动剂多肽衍生物治疗病毒性肝炎相关的肝纤维化 | |
| JPH10330284A (ja) | 肝細胞保護剤 | |
| CN115073582B (zh) | 多肽化合物及其在预防或治疗糖尿病或糖尿病并发症中的应用 | |
| CN117425489A (zh) | 用于离体器官护理的组合物 | |
| US8507446B2 (en) | Use of PEDF-derived polypeptides for treating liver cirrhosis | |
| CN103087153B (zh) | 一类新的抑制新生血管的小肽及其应用 | |
| WO2025196724A1 (en) | Methods for inducing immune responses | |
| KR102702011B1 (ko) | 폐내 염증의 완화 | |
| HK40095616A (en) | Glp-1r/gcgr dual-target agonist peptide derivatives for treatment of viral hepatitis-related hepatic fibrosis | |
| JP2026507086A5 (enExample) | ||
| JP2023522907A5 (enExample) | ||
| JPWO2001052901A1 (ja) | 遺伝子治療薬剤 |